{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:10:55Z","timestamp":1793506255503,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Heat shock proteins (Hsps), including Hsp90 and Hsp70, are intra- and extracellular molecules implicated in cellular homeostasis and immune processes and are induced by cell stress such as inflammation and infection. Autoimmune bullous disorders (AIBDs) and COVID-19 represent potentially life-threatening inflammatory and infectious diseases, respectively. A significant portion of AIBDs remain refractory to currently available immunosuppressive therapies, which may represent a risk factor for COVID-19, and suffer from treatment side-effects. Despite advances in vaccination, there is still a need to develop new therapeutic approaches targeting SARS-CoV-2, especially considering vaccine hesitancy, logistical distribution challenges, and breakthrough infections. In this mini review, we briefly summarize the role of targeting Hsp90\/70 as a promising double-edged sword in the therapy of AIBDs and COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1080786","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T05:07:10Z","timestamp":1671080830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting heat shock proteins 90 and 70: A promising remedy for both autoimmune bullous diseases and COVID-19"],"prefix":"10.3389","volume":"13","author":[{"given":"Michael","family":"Kasperkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Tukaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1002\/mco2.161","article-title":"Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities","author":"Hu","year":"2020","journal-title":"MedComm"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B4","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022","journal-title":"StatPearls Treasure Island (FL): StatPearls Publishing"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18538","article-title":"Rituximab in immunobullous disorders during the COVID-19 pandemic: A systematic review of observational studies","author":"Kasperkiewicz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221575","article-title":"Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations","volume":"81","author":"Kroon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18030","article-title":"Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12760","article-title":"Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases","volume":"24","author":"Tukaj","year":"2015","journal-title":"Exp Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/biom12081153","article-title":"Heat shock protein 90 (Hsp90) and Hsp70 as potential therapeutic targets in autoimmune skin diseases","volume":"12","author":"Tukaj","year":"2022","journal-title":"Biomolecules"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12476","article-title":"Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses","volume":"23","author":"Tukaj","year":"2014","journal-title":"Exp Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12680","article-title":"Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita","volume":"24","author":"Tukaj","year":"2015","journal-title":"Exp Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.032","article-title":"Topically applied Hsp90 blocker 17AAG inhibits autoantibody-mediated blister-inducing cutaneous inflammation","volume":"137","author":"Tukaj","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70496","DOI":"10.1371\/journal.pone.0070496","article-title":"Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid","volume":"8","author":"Tukaj","year":"2013","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-014-0513-8","article-title":"Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes","volume":"19","author":"Tukaj","year":"2014","journal-title":"Cell Stress Chaperones."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14495","article-title":"Evidence for a role of extracellular heat shock protein 70 in epidermolysis bullosa acquisita","volume":"31","author":"Tukaj","year":"2022","journal-title":"Exp Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877958","article-title":"Pathological relevance of anti-Hsp70 IgG autoantibodies in epidermolysis bullosa acquisita","volume":"13","author":"Tukaj","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9366","DOI":"10.3390\/ijms22179366","article-title":"Role of heat shock proteins (HSP70 and HSP90) in viral infection","volume":"22","author":"Lubkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2022-0008","article-title":"The capture of host cell\u2019s resources: The role of heat shock proteins and polyamines in SARS-COV-2 (COVID-19) pathway to viral infection","volume":"13","author":"Makhoba","year":"2022","journal-title":"Biomol Concepts"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/cells10113136","article-title":"Morphological alterations and stress protein variations in lung biopsies obtained from autopsies of COVID-19 subjects","volume":"10","author":"Barone","year":"2021","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.812199","article-title":"HSP90 inhibitors modulate SARS-CoV-2 spike protein subunit 1-induced human pulmonary microvascular endothelial activation and barrier dysfunction","volume":"13","author":"Colunga Biancatelli","year":"2022","journal-title":"Front Physiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102151","DOI":"10.1016\/j.isci.2021.102151","article-title":"Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy","volume":"24","author":"Wyler","year":"2021","journal-title":"iScience"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103412","DOI":"10.1016\/j.isci.2021.103412","article-title":"Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells","volume":"24","author":"Goswami","year":"2021","journal-title":"iScience"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1850183","article-title":"Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target","volume":"9","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202010188","article-title":"SARS-CoV-2 infection remodels the host protein thermal stability landscape","volume":"17","author":"Selkrig","year":"2021","journal-title":"Mol Syst Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-18714\/v1","article-title":"Drug repositioning suggests a role for the heat shock protein 90 inhibitor geldanamycin in treating COVID-19 infection","author":"Sultan","year":"2020","journal-title":"Res Sq"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.622271","article-title":"SARS-CoV-2 infection-induced promoter hypomethylation as an epigenetic modulator of heat shock protein A1L (HSPA1L) gene","volume":"12","author":"Muhammad","year":"2021","journal-title":"Front Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.02.026","article-title":"COVID-19 spike-host cell receptor GRP78 binding site prediction","volume":"80","author":"Ibrahim","year":"2020","journal-title":"J Infect"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.10.009","article-title":"Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants","volume":"85","author":"Elfiky","year":"2022","journal-title":"J Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.jbc.2021.100759","article-title":"The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection","volume":"296","author":"Carlos","year":"2021","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12192-020-01180-3","article-title":"Covid-19, heat shock proteins, and autoimmune bullous diseases: a potential link deserving further attention","volume":"26","author":"Kasperkiewicz","year":"2021","journal-title":"Cell Stress Chaperones."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-021-01215-3","article-title":"Autoantibodies to heat shock protein 60, 70, and 90 are not altered in the anti-SARS-CoV-2 IgG-seropositive humans without or with mild symptoms","volume":"26","author":"Mantej","year":"2021","journal-title":"Cell Stress Chaperones."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.807711","article-title":"Case report: Circulating anti-SARS-CoV-2 antibodies do not cross-react with pemphigus or pemphigoid autoantigens","volume":"8","author":"Kasperkiewicz","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.3390\/ijms21155298","article-title":"Heat shock protein 70 as a double agent acting inside and outside the cell: insights into autoimmunity","volume":"21","author":"Tukaj","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1080786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T05:07:15Z","timestamp":1671080835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1080786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2022.1080786"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1080786","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"1080786"}}